{"id":35756,"date":"2015-05-07T07:18:29","date_gmt":"2015-05-07T11:18:29","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=35756"},"modified":"2015-05-07T07:18:29","modified_gmt":"2015-05-07T11:18:29","slug":"plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756","title":{"rendered":"Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI) \u2013 Book Profit"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI)<\/strong>, a biopharmaceutical company, ended the session a huge 44% higher but registered the day high at $11.15, 86% higher than the previous day\u2019s closing price. It opened with a big gap and reached the day high within the first two hours but a bout of profit booking in the latter hours pushed the price a bit lower. The stock gained nearly 200% in the last two sessions with the volume reaching 65 million on each day against the daily average of 6 million only.<\/p>\n<p style=\"text-align: justify;\">The huge jump came on the back of Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI) announcing a definite agreement to acquire Abeona Therapeutics, a company that develops and commercializes therapies for patients with lysosomal storage diseases. The market has received the announcement with a lot of excitement. Upon closing of the transaction, Abeona Therapeutic members will be issued a total of 3,979,761 common shares by Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI), coupled with performance milestones up to an additional $9 million, in common stock or cash, depending on the company\u2019s choice.<\/p>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/05\/ptib.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\" size-full wp-image-35757 aligncenter\" src=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/05\/ptib.jpg\" alt=\"ptib\" width=\"661\" height=\"477\" srcset=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/05\/ptib.jpg 661w, https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/05\/ptib-300x216.jpg 300w, https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2015\/05\/ptib-76x55.jpg 76w\" sizes=\"(max-width: 661px) 100vw, 661px\" \/><\/a><\/p>\n<p style=\"text-align: justify;\">The deal has been unanimously approved by the board of directors of Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI) and the managers of Abeona. It is expected that the transaction will be closed by the end of 2015, subject to customary closing conditions.<\/p>\n<p style=\"text-align: justify;\">The main business of Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI) is the development of protein biologic therapies and oncology supportive care products and the product basket also includes the administration of oral mucositis in MuGard and treatment of radiation proctitis in Proctigard.<\/p>\n<p style=\"text-align: justify;\">Technically, the stock has hit a strong supply area around $11 and extending the rally anymore in the short term looks difficult. Investors could do better to book profits or at least keep a tight protective stop loss. The event based rally makes any recommendation of fresh investment at this point very unlikely.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI), a biopharmaceutical company, ended the session a huge 44% higher but registered the day high at $11.15, 86% higher than the [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":26999,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[11405,11404],"stock_ticker":[],"class_list":["post-35756","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqptbi","tag-plasmatech-biopharmaceuticals-inc-nasdaqptbi","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI) \u2013 Book Profit - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI) \u2013 Book Profit - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI), a biopharmaceutical company, ended the session a huge 44% higher but registered the day high at $11.15, 86% higher than the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-05-07T11:18:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/07\/CTI-BioPharma-Corp1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"216\" \/>\n\t<meta property=\"og:image:height\" content=\"234\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Steve Hackney\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Steve Hackney\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756\"},\"author\":{\"name\":\"Steve Hackney\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\"},\"headline\":\"Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI) \u2013 Book Profit\",\"datePublished\":\"2015-05-07T11:18:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756\"},\"wordCount\":311,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/07\/CTI-BioPharma-Corp1.jpg\",\"keywords\":[\"NASDAQ:PTBI\",\"Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756\",\"name\":\"Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI) \u2013 Book Profit - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/07\/CTI-BioPharma-Corp1.jpg\",\"datePublished\":\"2015-05-07T11:18:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/07\/CTI-BioPharma-Corp1.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/07\/CTI-BioPharma-Corp1.jpg\",\"width\":216,\"height\":234},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI) \u2013 Book Profit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\",\"name\":\"Steve Hackney\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"caption\":\"Steve Hackney\"},\"description\":\"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI) \u2013 Book Profit - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756","og_locale":"en_US","og_type":"article","og_title":"Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI) \u2013 Book Profit - Wall Street PR","og_description":"Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI), a biopharmaceutical company, ended the session a huge 44% higher but registered the day high at $11.15, 86% higher than the [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2015-05-07T11:18:29+00:00","og_image":[{"width":216,"height":234,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/07\/CTI-BioPharma-Corp1.jpg","type":"image\/jpeg"}],"author":"Steve Hackney","twitter_misc":{"Written by":"Steve Hackney","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756"},"author":{"name":"Steve Hackney","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867"},"headline":"Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI) \u2013 Book Profit","datePublished":"2015-05-07T11:18:29+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756"},"wordCount":311,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/07\/CTI-BioPharma-Corp1.jpg","keywords":["NASDAQ:PTBI","Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756","url":"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756","name":"Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI) \u2013 Book Profit - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/07\/CTI-BioPharma-Corp1.jpg","datePublished":"2015-05-07T11:18:29+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/07\/CTI-BioPharma-Corp1.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/07\/CTI-BioPharma-Corp1.jpg","width":216,"height":234},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/plasmatech-biopharmaceuticals-inc-nasdaqptbi-book-profit-35756#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Plasmatech Biopharmaceuticals Inc (NASDAQ:PTBI) \u2013 Book Profit"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867","name":"Steve Hackney","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","caption":"Steve Hackney"},"description":"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=35756"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35756\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/26999"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=35756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=35756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=35756"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=35756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}